Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian K Link

Showing results (91-100 of 231) with videos related to

Pageof 24
Sort By:
Leukemia & Lymphoma|July 18, 2012
The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphomaKathleen J Yost, Carrie A Thompson, David T Eton, et al.
American Journal of Hematology|June 8, 2012
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patientsStephen M Ansell, Matthew J Maurer, Steven C Ziesmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyCarla Casulo, Michelle Byrtek, Keith L Dawson, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.
Leukemia & Lymphoma|April 20, 2013
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus statusHervé Ghesquières, Ahmet Dogan, Brian K Link, et al.
JCO Oncology Practice|December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research AgendaBryan Valcarcel, Kerry J Savage, Brian K Link, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
Blood|June 16, 2011
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaIvana N M Micallef, Matthew J Maurer, Gregory A Wiseman, et al.
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Follicular lymphoma in the United States: first report of the national LymphoCare studyJonathan W Friedberg, Michael D Taylor, James R Cerhan, et al.
Pageof 24

Showing results (91-100 of 231) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|July 18, 2012
The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphomaKathleen J Yost, Carrie A Thompson, David T Eton, et al.
American Journal of Hematology|June 8, 2012
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patientsStephen M Ansell, Matthew J Maurer, Steven C Ziesmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2015
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare StudyCarla Casulo, Michelle Byrtek, Keith L Dawson, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.
Leukemia & Lymphoma|April 20, 2013
FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus statusHervé Ghesquières, Ahmet Dogan, Brian K Link, et al.
JCO Oncology Practice|December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research AgendaBryan Valcarcel, Kerry J Savage, Brian K Link, et al.
Leukemia & Lymphoma|August 5, 2011
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaClive S Zent, Brian J Smith, Zuhair K Ballas, et al.
Blood|June 16, 2011
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaIvana N M Micallef, Matthew J Maurer, Gregory A Wiseman, et al.
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Follicular lymphoma in the United States: first report of the national LymphoCare studyJonathan W Friedberg, Michael D Taylor, James R Cerhan, et al.
Pageof 24